ilmscore | Prediction Details
"for Doctor Reddy's it would be almost 50% of their overall profits that is coming from generic revenue... you can basically understand the impact companies will Will face once generic revision comes off from the base the extent of earnings detorsion you can you can very well gauge"
By Groww | April 24, 2025 | Pending
From video
Sensex, Nifty rally pauses; FMCG & realty stocks fall | Tariff-proofing your pharma portfolio 00:22:40 - 00:23:07
Interpreted Prediction
Dr. Reddy's is predicted to face a significant impact on its overall profits (approximately 50% derived from generic revenue) once generic Revlimid exclusivity expires in January 2026.

Prediction Details

Ticker
DRREDDY

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.